Literature DB >> 26955836

Effect of alendronate on the progression of periodontitis induced by Porphyromonas gingivalis and Fusobacterium nucleatum: a study in rats.

Carmen L Mueller Storrer1, Tatiana Miranda Deliberador2, Allan Fernando Giovanini2, Viviane Crivellaro2, João Cesar Zielak2, Giuseppe Alexandre Romito3.   

Abstract

OBJECTIVE: The study aimed to investigate the effect of alendronate (ALN) on the inhibition of alveolar bone loss in experimental periodontitis in Wistar rats.
MATERIALS AND METHODS: Periodontitis was induced by oral inoculation of Porphyromonas gingivalis with Fusobacterium nucleatum. The rats (n = 80) were randomized as follows: negative control (n = 10); positive control (n = 10); ALN groups: test 8 (n = 10), test 12 (n = 10), and test 16 (n = 10); and placebo groups: control 8 (n = 10), control 12 (n = 10), and control 16 (n = 10). Two milligrams per kilogram of ALN or placebo was administered twice weekly for 8, 12, and 16 weeks. Bone loss was determined by morphological and histological analyses. One independent, blinded examiner (ICC, 0.91) performed the measurements. The distance from the cement enamel junction to the alveolar bone crest of the second lower molar was measured: distal-vestibular (d), furca (f), mesial-vestibular (h), and area. Histometry was performed on the second contralateral molar. Sections (6 μm) were used to determine the furcation bone area (A-FB). The following statistical analyses were conducted: Mann-Whitney and Kruskal-Wallis.
RESULTS: PC group developed periodontitis (p < 0.0001). Morphometric analysis determined that ALN was effective in T8 for linear measurements d, f, and h (p < 0.05). No significant differences occurred at test 8, test 12, and test 16. Analysis of A-FB revealed no significant differences between the ALN and placebo groups at 8 and 16 weeks (p > 0.05). ALN was effective against bone loss in relation to A-FB after 12 weeks (p < 0.0001).
CONCLUSIONS: According to the methodology used, the results suggest that oral administration of ALN could influence alveolar bone loss in rats submitted to experimental periodontitis. CLINICAL RELEVANCE: ALN could be a potential therapeutic approach when associated with periodontal treatment.

Entities:  

Keywords:  Alendronate; Bisphosphonates; Bone resorption; Fusobacterium nucleatum; Oral infection; Periodontitis; Porphyromonas gingivalis

Mesh:

Substances:

Year:  2016        PMID: 26955836     DOI: 10.1007/s00784-016-1769-4

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  41 in total

Review 1.  Oral microbiology and genomics.

Authors:  Margaret J Duncan
Journal:  Periodontol 2000       Date:  2005       Impact factor: 7.589

2.  Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.

Authors:  Salvatore L Ruggiero; John Fantasia; Eric Carlson
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2006-07-31

3.  Impact of Porphyromonas gingivalis inoculation on ligature-induced alveolar bone loss. A pilot study in rats.

Authors:  T Meulman; D C Peruzzo; R N Stipp; P F Gonçalves; E A Sallum; M Z Casati; R B Goncalves; F H Nociti
Journal:  J Periodontal Res       Date:  2011-07-04       Impact factor: 4.419

4.  Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats.

Authors:  K Shoji; H Horiuchi; H Shinoda
Journal:  J Periodontal Res       Date:  1995-07       Impact factor: 4.419

5.  Disodium chlodronate prevents bone resorption in experimental periodontitis in rats.

Authors:  Veruska B M Alencar; Mirna M Bezerra; Vilma Lima; André Luis C Abreu; Gerly Anne C Brito; Francisco Airton C Rocha; Ronaldo A Ribeiro
Journal:  J Periodontol       Date:  2002-03       Impact factor: 6.993

6.  Autogenous bone graft with or without a calcium sulfate barrier in the treatment of Class II furcation defects: a histologic and histometric study in dogs.

Authors:  Tatiana M Deliberador; Maria J H Nagata; Flávia A C Furlaneto; Luiz G N Melo; Tetuo Okamoto; Maria L M M Sundefeld; Stephen E Fucini
Journal:  J Periodontol       Date:  2006-05       Impact factor: 6.993

7.  The influence of alendronate on bone formation and resorption in a rat ectopic bone development model.

Authors:  Avinoam Yaffe; Ron Kollerman; Hila Bahar; Itzhak Binderman
Journal:  J Periodontol       Date:  2003-01       Impact factor: 6.993

8.  Effects of a bisphosphonate on experimental periodontitis in monkeys.

Authors:  M A Brunsvold; E S Chaves; K S Kornman; T B Aufdemorte; R Wood
Journal:  J Periodontol       Date:  1992-10       Impact factor: 6.993

9.  Ultrastructural and immunohistochemical study of the effect of sodium alendronate in the progression of experimental periodontitis in rats.

Authors:  Mariana M Moreira; Vivian Bradaschia-Correa; Natasha D M Marques; Lorraine Braga Ferreira; Victor E Arana-Chavez
Journal:  Microsc Res Tech       Date:  2014-08-07       Impact factor: 2.769

10.  Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.

Authors:  M Rossini; D Gatti; N Zamberlan; V Braga; R Dorizzi; S Adami
Journal:  J Bone Miner Res       Date:  1994-11       Impact factor: 6.741

View more
  2 in total

1.  Prolonged use of alendronate alters the biology of cranial repair in estrogen-deficient rats' associated simultaneous immunohistochemical expression of TGF-β1+, α-ER+, and BMPR1B.

Authors:  Allan Fernando Giovanini; Giuliene Nunes de Sousa Passoni; Isabella Göhringer; Tatiana Miranda Deliberador; João Cesar Zielak; Carmem Lucia Muller Storrer; Thais Andrade Costa-Casagrande; Rafaela Scariot
Journal:  Clin Oral Investig       Date:  2017-12-02       Impact factor: 3.573

Review 2.  Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies.

Authors:  Angelica Leticia Reis Pavanelli; Bruna Silva de Menezes; Erica Bianca Barbosa Pereira; Fabio Assuncao de Souza Morais; Joni Augusto Cirelli; Rafael Scaf de Molon
Journal:  Biomed Res Int       Date:  2022-05-02       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.